SG11202101502YA - Anti-gdf15 antibodies, compositions and methods of use - Google Patents
Anti-gdf15 antibodies, compositions and methods of useInfo
- Publication number
- SG11202101502YA SG11202101502YA SG11202101502YA SG11202101502YA SG11202101502YA SG 11202101502Y A SG11202101502Y A SG 11202101502YA SG 11202101502Y A SG11202101502Y A SG 11202101502YA SG 11202101502Y A SG11202101502Y A SG 11202101502YA SG 11202101502Y A SG11202101502Y A SG 11202101502YA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- methods
- gdf15 antibodies
- gdf15
- antibodies
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862765289P | 2018-08-20 | 2018-08-20 | |
US201862750393P | 2018-10-25 | 2018-10-25 | |
US201862750479P | 2018-10-25 | 2018-10-25 | |
US201962881064P | 2019-07-31 | 2019-07-31 | |
PCT/IB2019/056932 WO2020039321A2 (en) | 2018-08-20 | 2019-08-15 | Anti-gdf15 antibodies, compositions and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202101502YA true SG11202101502YA (en) | 2021-03-30 |
Family
ID=69232873
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202101502YA SG11202101502YA (en) | 2018-08-20 | 2019-08-15 | Anti-gdf15 antibodies, compositions and methods of use |
Country Status (16)
Country | Link |
---|---|
US (2) | US11566066B2 (en) |
EP (1) | EP3841121A2 (en) |
JP (2) | JP7155403B2 (en) |
KR (1) | KR20210049840A (en) |
CN (1) | CN112912395A (en) |
AU (1) | AU2019323790A1 (en) |
BR (1) | BR112021003173A2 (en) |
CA (1) | CA3109905A1 (en) |
CO (1) | CO2021001893A2 (en) |
IL (1) | IL280963A (en) |
MX (1) | MX2021001841A (en) |
PE (1) | PE20211412A1 (en) |
PH (1) | PH12021550337A1 (en) |
SG (1) | SG11202101502YA (en) |
TW (1) | TWI803682B (en) |
WO (1) | WO2020039321A2 (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2900263B1 (en) | 2012-09-26 | 2019-06-05 | Julius-Maximilians-Universität Würzburg | Monoclonal antibodies to growth and differentiation factor 15 (gdf-15) |
US11464856B2 (en) | 2015-10-02 | 2022-10-11 | Julius-Maximilians-Universität Würzburg | Combination therapy using inhibitors of human growth and differentiation factor 15 (GDF-15) and immune checkpoint blockers |
CN112912395A (en) | 2018-08-20 | 2021-06-04 | 辉瑞公司 | anti-GDF 15 antibodies, compositions, and methods of use |
US20230212274A1 (en) * | 2020-02-21 | 2023-07-06 | The Children's Medical Center Corporation | Method for treating asthma or allergic disease |
CN115968285A (en) * | 2020-03-18 | 2023-04-14 | Gmp生物技术有限公司 | TGF-beta inhibition, agents and compositions therefor |
US20230338396A1 (en) * | 2020-05-14 | 2023-10-26 | Augusta University Research Institute, Inc. | Cannabidiol as a therapeutic modality for covid-19 |
JPWO2022092326A1 (en) * | 2020-10-30 | 2022-05-05 | ||
IL302646A (en) * | 2020-11-10 | 2023-07-01 | Catalym Gmbh | Anti-gdf15 antibody and a dosage regimen for the treatment of cancer |
TWI839729B (en) * | 2021-05-07 | 2024-04-21 | 大陸商信達生物製藥(蘇州)有限公司 | Fc MUTANTS WITH MODIFIED BINDING CAPACITY TO Fc RECEPTORS |
WO2022255401A1 (en) * | 2021-06-03 | 2022-12-08 | 国立大学法人 東京大学 | Disease marker expressed in association with abnormal erk-mapk pathway activation |
CA3228576A1 (en) * | 2021-08-10 | 2023-02-16 | Byomass Inc. | Anti-gdf15 antibodies, compositions and uses thereof |
WO2023039359A1 (en) * | 2021-09-10 | 2023-03-16 | Ngm Biopharmaceuticals, Inc. | Methods of treating cancer and tumor-related weight loss and cachexia |
WO2023048425A1 (en) * | 2021-09-24 | 2023-03-30 | 재단법인대구경북과학기술원 | Gfral-antagonistic antibody having improved affinity, and use thereof |
WO2023079430A1 (en) * | 2021-11-02 | 2023-05-11 | Pfizer Inc. | Methods of treating mitochondrial myopathies using anti-gdf15 antibodies |
WO2023122213A1 (en) | 2021-12-22 | 2023-06-29 | Byomass Inc. | Targeting gdf15-gfral pathway cross-reference to related applications |
WO2023141815A1 (en) * | 2022-01-26 | 2023-08-03 | 康源博创生物科技(北京)有限公司 | Antibody molecule against growth and differentiation factor 15 and use thereof |
WO2023217068A1 (en) * | 2022-05-09 | 2023-11-16 | 舒泰神(北京)生物制药股份有限公司 | Antibody that specifically recognizes gdf15 and use thereof |
CN116444667B (en) * | 2023-06-13 | 2023-09-01 | 上海驯鹿生物技术有限公司 | GDF 15-targeted fully-humanized antibody and application thereof |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4754065A (en) | 1984-12-18 | 1988-06-28 | Cetus Corporation | Precursor to nucleic acid probe |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
AR039067A1 (en) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | ANTIBODIES FOR CD40 |
AU2002357060A1 (en) | 2001-12-03 | 2003-06-17 | Abgenix, Inc. | Antibody categorization based on binding characteristics |
CN102746399B (en) | 2002-12-24 | 2016-03-02 | 里纳特神经***学公司 | Anti-ngf antibodies and using method thereof |
EP2774620A1 (en) | 2004-04-13 | 2014-09-10 | St Vincent's Hospital Sydney Limited | Method for modulating weight loss |
EP2783698A1 (en) | 2007-08-16 | 2014-10-01 | St Vincent's Hospital Sydney Limited | Agents and methods for modulating macrophage inhibitory cytokine (MIC-1) activity |
EP2324055A2 (en) | 2008-08-25 | 2011-05-25 | Amplimmune, Inc. | Pd-1 antagonists and methods of use thereof |
JP2013512251A (en) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Simultaneous inhibition of PD-L1 / PD-L2 |
MY166429A (en) * | 2010-11-17 | 2018-06-26 | Chugai Pharmaceutical Co Ltd | Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii |
US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
SG11201402603WA (en) | 2011-11-28 | 2014-06-27 | Merck Patent Gmbh | Anti-pd-l1 antibodies and uses thereof |
US9175076B2 (en) * | 2012-12-21 | 2015-11-03 | Aveo Pharmaceuticals, Inc. | Anti-GDF15 antibodies |
JP6865585B2 (en) * | 2014-03-26 | 2021-04-28 | ユリウス・マクシミリアンス−ウニヴェルジテート・ヴュルツブルクJulius Maximilians−Universitaet Wuerzburg | Monoclonal antibody against growth differentiation factor 15 (GDF-15) and its use for treating cancer cachexia and cancer |
US20170137505A1 (en) | 2014-06-20 | 2017-05-18 | Aveo Pharmaceuticals, Inc. | Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulator |
DK3197493T3 (en) | 2014-09-25 | 2021-05-31 | Aveo Pharmaceuticals Inc | PROCEDURES FOR CONVERSION OF COACHE AND EXTENSION OF SURVIVAL INCLUDING ADMINISTRATION OF A GDF15 MODULATOR AND AN ANTI-CANCER |
TWI595006B (en) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | Anti-pd-1 antibodies and methods of use thereof |
US10647756B2 (en) | 2015-05-18 | 2020-05-12 | Pfizer Inc. | Humanized antibodies |
CN112912395A (en) * | 2018-08-20 | 2021-06-04 | 辉瑞公司 | anti-GDF 15 antibodies, compositions, and methods of use |
-
2019
- 2019-08-15 CN CN201980069329.4A patent/CN112912395A/en active Pending
- 2019-08-15 WO PCT/IB2019/056932 patent/WO2020039321A2/en active Application Filing
- 2019-08-15 CA CA3109905A patent/CA3109905A1/en active Pending
- 2019-08-15 SG SG11202101502YA patent/SG11202101502YA/en unknown
- 2019-08-15 JP JP2021509185A patent/JP7155403B2/en active Active
- 2019-08-15 BR BR112021003173-1A patent/BR112021003173A2/en unknown
- 2019-08-15 MX MX2021001841A patent/MX2021001841A/en unknown
- 2019-08-15 PE PE2021000234A patent/PE20211412A1/en unknown
- 2019-08-15 EP EP19842836.9A patent/EP3841121A2/en active Pending
- 2019-08-15 KR KR1020217007930A patent/KR20210049840A/en active IP Right Grant
- 2019-08-15 AU AU2019323790A patent/AU2019323790A1/en active Pending
- 2019-08-15 TW TW108129121A patent/TWI803682B/en active
- 2019-08-15 US US16/541,817 patent/US11566066B2/en active Active
-
2021
- 2021-02-17 PH PH12021550337A patent/PH12021550337A1/en unknown
- 2021-02-17 CO CONC2021/0001893A patent/CO2021001893A2/en unknown
- 2021-02-18 IL IL280963A patent/IL280963A/en unknown
-
2022
- 2022-08-01 US US17/816,484 patent/US20220380448A1/en active Pending
- 2022-10-05 JP JP2022160619A patent/JP2022188191A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
PH12021550337A1 (en) | 2021-10-04 |
KR20210049840A (en) | 2021-05-06 |
US20200055930A1 (en) | 2020-02-20 |
WO2020039321A3 (en) | 2020-05-07 |
US20220380448A1 (en) | 2022-12-01 |
IL280963A (en) | 2021-04-29 |
CA3109905A1 (en) | 2020-02-27 |
TWI803682B (en) | 2023-06-01 |
MX2021001841A (en) | 2021-05-13 |
US11566066B2 (en) | 2023-01-31 |
CN112912395A (en) | 2021-06-04 |
TW202021619A (en) | 2020-06-16 |
JP2022188191A (en) | 2022-12-20 |
EP3841121A2 (en) | 2021-06-30 |
JP7155403B2 (en) | 2022-10-18 |
CO2021001893A2 (en) | 2021-03-08 |
JP2021526847A (en) | 2021-10-11 |
BR112021003173A2 (en) | 2021-05-11 |
AU2019323790A1 (en) | 2021-03-11 |
WO2020039321A2 (en) | 2020-02-27 |
PE20211412A1 (en) | 2021-08-02 |
WO2020039321A8 (en) | 2020-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL280963A (en) | Anti-gdf15 antibodies, compositions and methods of use | |
IL272367A (en) | Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies | |
IL276731A (en) | Anti-cd73 antibodies and methods of use thereof | |
ZA202102034B (en) | Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies | |
IL278821A (en) | Anti-sirpa antibodies and methods of use thereof | |
SG11202010909RA (en) | Anti-msr1 antibodies and methods of use thereof | |
IL283754A (en) | Anti-claudin antibodies, compositions comprising same and uses thereof | |
IL270214A (en) | Anti-sortilin antibodies and methods of use thereof | |
IL280317A (en) | Anti-avb8 antibodies and compositions and uses thereof | |
IL277212A (en) | Anti-klk5 antibodies and methods of use | |
IL279648A (en) | Anti-sirp-beta1 antibodies and methods of use thereof | |
EP3720481A4 (en) | Anti-dclk1 antibodies and chimeric antigen receptors, and compositions and methods of use thereof | |
SG11202011227VA (en) | Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof | |
IL283884A (en) | Anti-il-36 antibodies and methods of use thereof | |
IL282939A (en) | Mixtures and compositions comprising 5-fluoro-4-imino-3- methyl-1-tosyl-3,4- dihydropyrimidin-2-one, and methods of use thereof | |
IL280338A (en) | Anti-siglec-5 antibodies and methods of use thereof | |
IL280280A (en) | Compositions of fcrn antibodies and methods of use thereof | |
IL277786A (en) | Aav compositions, methods of making and methods of use | |
SG11202011041YA (en) | Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof | |
IL279227A (en) | Anti-siglec-7 antibodies and methods of use thereof | |
EP3735246A4 (en) | Mito-lonidamine, compositions and methods of use | |
GB201800461D0 (en) | Novel combination and use of antibodies | |
GB201800395D0 (en) | Novel combination and use of antibodies |